| LFMD | |
| Formerly | ImmuDyne, Inc. Conversion Labs, Inc. |
| Company type | Public |
| Industry | Telehealth |
| Founded | May 24, 1994 in New York City, United States |
Key people | Justin Schreiber, CEO Bobby Jindal, Board member [1] |
| Website | lifemd |
| Footnotes /references [2] | |
LifeMD, Inc. is a publicly traded American telehealth company. [3] It gives subscribers access to doctors and nurse practitioners for virtual medical consultations and treatments with prescription medications. [4]
The company was founded as ImmuDyne, Inc. in 1994 and completed its initial public offering in 2001. [5] In 2018, it rebranded as Conversion Labs, Inc. with Justin Schreiber named chief executive officer. [6] The company changed its name to LifeMD in 2020 and started using the ticker name LFMD. [7] [8]
In the first quarter of 2025, LifeMD reported that total revenues increased 49% YoY to $65.7 million. [9]
In June 2023, LifeMD announced a weight management program to prescribe GLP-1 medications upon meeting requirements in a virtual appointment with a clinician. [10] It began a pilot program with Medifast, which later announced a partnership between the companies to connect each other's customers. LifeMD also received a $20 million investment from Medifast at that time. [11]
The company introduced private health insurance acceptance in 2024. [12]
In March 2025, LifeMD signed an agreement to offer Eli Lilly’s weight-loss drug Zepbound to self-paying patients. Specifically, a deal was signed with LillyDirect’s pharmacy partner, through which vials of Zepbound are sold at discounts for cash-pay customers. LifeMD’s stock surged in 2025 after a deal with Novo Nordisk to offer Wegovy through the LifeMD platform at a discounted price. [13]
In April 2025, LifeMD acquired women’s health virtual care provider Optimal Human Health MD, to establish a foundation of hormone health, metabolism, and bone density on its platform. [14]